



## Twist Bioscience Expands Express Delivery Turnaround Time to All Gene Fragments Regardless of Format

July 7, 2025

Twist Gene Fragments shipped starting at two business days regardless of length, volume, configuration or delivery format

Gene Fragments pricing from seven cents per base regardless of configuration, no hidden fees

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 7, 2025-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today accelerated its Express turnaround time for all [Twist Gene Fragments](#) with a turnaround time starting at two business days for both adapters off and adapters on configurations.

"We continue to iterate our manufacturing processes, enhancing and expanding our products to meet our customers' needs," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Our customers receive the same high quality Twist Gene Fragments in the format they want, the scale that they need, now with the Express turnaround time regardless of configuration. Leveraging our highly automated workflow and scalable infrastructure, our pricing from seven cents per base pair for all Gene Fragment configurations, with no additional fees, allows transparency, affordability and flexibility to enable myriad applications across industries."

Twist Gene Fragments are designed to simplify the process of ordering synthetic DNA by offering a reliable and cost-effective solution for researchers. Fragments ship within two to four business days, for one or tens of thousands of Gene Fragments. Twist provides flexible delivery formats including tubes, plates, normalization and resuspension, as well as adapter addition, without impact to turnaround time or cost. Twist will offer gene fragments without adapters as a standard offering, eliminating the fee previously charged for removing adapters. At Twist, we deliver Gene Fragments quickly, with a typical processing time of just 2–4 business days before turning your product over to the shipping carrier. This rapid turnaround time reflects the efficiency of our state-of-the-art facilities, ensuring orders are manufactured quickly and reliably.

With the lowest industry error rate of 1:7500, researchers can reduce the time spent picking colonies or troubleshooting mutations, improving confidence in downstream applications.

### Twist Gene Fragments

[Twist Gene Fragments](#) are universally compatible with all downstream cloning methods, allowing for seamless integration into a wide array of applications. They can be utilized in protein engineering, antibody discovery, pathway engineering, functional genomics, diagnostic assays and other fields. Twist Gene Fragments are customizable and have no order limit. Turnaround time for Gene Fragments 0.3-5.0kb in length starts at two business days regardless of configuration.

### About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture and industrial chemicals, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit [www.twistbioscience.com](http://www.twistbioscience.com).

Follow us on [LinkedIn](#) | [X](#) | [YouTube](#) | [Instagram](#) | [Bluesky](#)

### Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the continued improvements to our manufacturing processes and products to meet future customer needs, and the expected benefits of such improvements. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-

looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250707956038/en/): <https://www.businesswire.com/news/home/20250707956038/en/>

**For Investors:**

Angela Bitting  
SVP, Corporate Affairs  
925-202-6211  
[abitting@twistbioscience.com](mailto:abitting@twistbioscience.com)

**For Media:**

Amanda Houlihan  
Communications Manager  
774-265-5334  
[ahoulihan@twistbioscience.com](mailto:ahoulihan@twistbioscience.com)

Source: Twist Bioscience Corporation